LCD L36117: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — CGS
Policy LCD-L36117 · Hematology
New genetic testing LCD affects billing for myeloproliferative disease.
Code intelligence
D47.9 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code D47.9.
Elevated code riskView ICD-10 detail
Signal breakdown
4 shown · 4 total in platform
Risk: Elevated
0
Critical
0%
1
High
25%
3
Routine
75%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
High
LCD L39923: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Noridian
Policy LCD-L39923 · Hematology
Changes in billing for myeloproliferative neoplasms testing ahead.
LCD L40000: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — CGS
Policy LCD-L40000 · Hematology
New LCD impacts billing for myeloproliferative neoplasms testing.
LCD L38176: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies — WPS
Policy LCD-L38176 · Oncology
New LCD affects billing for myeloid malignancy tests.
Audit documentation
Building an audit file that includes D47.9?
The Tripwire Audit Pack exports 12 months of Hematology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Hematology audit pack — $349One-time purchase · not a subscription